Ticker: DHR

Danaher

Healthcare Healthcare Medical - Diagnostics & Research
Price 201.01
Reco Buy Potential 60 Risk 59 Updated 2026-09-10

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Danaher Corporation operates in the healthcare sector, focusing on designing, manufacturing, and marketing innovative products and services. Its core offerings include life sciences, diagnostics, and environmental and applied solutions. Major business segments consist of Life Sciences, Diagnostics, and Water Quality, with primary revenue sources stemming from laboratory instruments, reagents, and software solutions that enhance healthcare and environmental testing.

Investment Profile

The investment profile of Danaher is more aligned with balanced investors, given its moderate dividend yield and growth potential. The company demonstrates consistent revenue growth, making it suitable for those seeking a combination of capital appreciation and income. Its established market position and diversified product range contribute to a stable investment outlook.

Fundamental metrics (experimental) Updated: 2026-09-10
EPS (TTM) — earnings per share for the last 12 months, $
5.19
Revenue QoQ — quarter-over-quarter revenue growth
-13.0%
EPS surprise
3.2%
20d volatility
1.8%
Dividend yield
0.9%
last ex-date
2026-03-27
AI recommendation changes
Date Before After Reason
2026-09-04 Sell Buy Mixed performance; fundamentals show weakness and uncertainty.
2026-09-02 Hold Sell Weak fundamentals and negative momentum raise concerns.
2026-08-31 Buy Hold Mixed performance; cautious due to revenue decline.
Analyst forecasts
Date Analyst Action Target Price Then
2026-09-09 UBS Update — → 250 205.2
2026-07-22 Deutsche Bank Target Lowered 250 → 240 175.03
2026-07-22 RBC Capital Target Raised 200 → 215 179.14
News Page 1 of 1
Masimo Danaher

Analysts expect Danaher (DHR) to accelerate earnings growth following Masimo acquisition and recovery in bioprocessing demand

Danaher is positioned for a significant earnings recovery as it emerges from a pandemic-induced destocking cycle, bolstered by its recent acquisition of Masimo and a rebound in bioprocessing demand. Investors may find the stock undervalued given its improving fundamentals and growth catalysts.
IQVIA Vertex Pharmaceuticals Danaher

Analysts highlight IQVIA (IQV) and Danaher (DHR) as leading biotech stocks poised for recovery

The biotechnology sector, which has faced significant challenges in recent years, is showing signs of recovery, presenting potential investment opportunities in companies like IQVIA, Danaher, and Vertex Pharmaceuticals. This shift is driven by stabilizing funding conditions, increased clinical trial activity, and the need for pharmaceutical companies to innovate as patent expirations loom.